The Emirates Drug Establishment (EDE) has signed a memorandum of understanding (MoU) with global healthcare company Viatris to strengthen local pharmaceutical manufacturing, attract investment and support the development of the UAE’s life sciences sector. The partnership aims to combine international expertise and advanced technologies with national capabilities to enhance the country’s pharmaceutical industry and strengthen its position as a regional manufacturing hub.
The MoU was signed by Dr. Fatima Al Kaabi, Director-General of the Emirates Drug Establishment, and Dr. Tamer Elsallab, Head of GCC and Levant Cluster at Viatris.
Click here to join our WhatsApp channel here
As part of the collaboration, Viatris has also signed a separate agreement with UAE-based ADCAN Pharma to localise the manufacturing of selected products from its portfolio. The agreement will support technology and knowledge transfer, strengthen cooperation between international and local pharmaceutical companies, and expand domestic production capabilities.
Dr. Fatima Al Kaabi said, “Our partnership with Viatris reflects the Emirates Drug Establishment’s commitment to establishing a model for international partnerships that transforms cooperation with global companies into long-term industrial and knowledge-based projects within the UAE. We are working to expand this model to attract high-value investments and develop joint projects with national manufacturers, further strengthening the UAE’s position in global pharmaceutical value chains.”
Also read: CE-Ventures Backs Oyster Therapeutics in USD 60 Million Series A Financing
The collaborations are also expected to strengthen pharmaceutical security, improve the continuous availability of medical products and increase the contribution of the pharmaceutical sector to the UAE’s healthcare and economic development.
